Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
286.98
-6.47 (-2.20%)
At close: May 15, 2026, 4:00 PM EDT
293.80
+6.82 (2.38%)
After-hours: May 15, 2026, 7:34 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 28 analysts polled by S&P Global, Alnylam Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $449.48. The average 1-year stock price forecast is 56.62% higher than the current stock price, while the lowest is $310 (+8.02%) and the highest is $566 (+97.23%).
Price Target: $449.48 (+56.62%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 13 | 13 | 13 | 12 | 12 |
| Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Hold | 5 | 5 | 5 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 28 | 28 | 29 | 28 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +77.71% | May 5, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $450 → $445 | Buy | Maintains | $450 → $445 | +55.06% | May 1, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $376 → $377 | Hold | Maintains | $376 → $377 | +31.37% | May 1, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $515 → $505 | Strong Buy | Maintains | $515 → $505 | +75.97% | Apr 13, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $425 | Strong Buy | Maintains | $425 | +48.09% | Mar 25, 2026 |
Financial Forecast
Revenue This Year
5.70B
from 3.71B
Increased by 53.40%
Revenue Next Year
7.50B
from 5.70B
Increased by 31.58%
EPS This Year
7.09
from 2.33
Increased by 204.31%
EPS Next Year
11.28
from 7.09
Increased by 59.14%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 6.5B | 9.5B | ||||||
| Avg | 5.7B | 7.5B | ||||||
| Low | 5.1B | 6.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 74.0% | 66.3% | ||||||
| Avg | 53.4% | 31.6% | ||||||
| Low | 37.4% | 14.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.98 | 15.96 | ||||||
| Avg | 7.09 | 11.28 | ||||||
| Low | 3.57 | 6.72 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 328.1% | 125.1% | ||||||
| Avg | 204.3% | 59.1% | ||||||
| Low | 53.1% | -5.2% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.